Navigation Links
NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Date:4/1/2009

upon achievement of certain development and regulatory milestones, the development and potential benefits of, and the market opportunities for, NovaBay's product candidates, as well as other statements that relate to future events or results, are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to: the risk that NovaBay may incur unexpected charges or need to or determined to engage in research and development not previously planned, which will cause NovaBay's cash burn to be greater than it expects; risks and uncertainties relating to difficulties or delays in discovery, development, testing, production and marketing of the company's product candidates; unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates; the uncertainty of patent protection for the company's intellectual property or trade secrets; the company's ability to obtain additional financing as necessary; results obtained in animal models may not be obtained in humans; and the risk of unexpected delays in the regulatory process which may delay the commencement or completion of clinical trials. Other risks relating to NovaBay and Aganocide(R) compounds, including risks that could cause actual results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Annual Report on Form 10-K for the period ended December 31, 2008, under the caption "Risk Factors" in Item 1A of Part I of that report, filed with the Securities and Exchange Commission on March 31, 2009. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revis
'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
2. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
3. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
6. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
10. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... DALLAS , June 29, 2015 ... Type (DNA, RNA, XNA), by Application (Diagnostics, Therapeutics, R&D), by ... Biotechnology & Pharmaceutical Companies, CRO) - Global Forecast to 2020", ... reach $244.93 Million by 2020 from $107.56 Million in 2015, ... market T ables and 67 F ...
(Date:6/26/2015)... MILFORD, Mass. , June 26, 2015 /PRNewswire/ ... in vitro diagnostics manufacturers, today announced that it ... (CRADA) with the National Cancer Institute (NCI), part ... reference materials and positive controls for cancer assays. ... to mix and accurately quantitate control DNA biosynthetics ...
(Date:6/26/2015)... MUMBAI, India , June 26, 2015 ... a leading global IT services, consulting and business solutions ... Leader in Worldwide Life Sciences R&D Risk-Based Monitoring by ... MarketScape: Worldwide Life Science R&D Risk-Based Monitoring 2015 Vendor ... The report evaluated eight leading IT services vendors with ...
(Date:6/26/2015)... , ... June 26, 2015 , ... ReliantHeart, Inc. ... indicates that from the first implant of the HeartAssist5® LVAD (HA5) to the 68th ... HA5. , Thrombus that originates in an LVAD is referred to as de ...
Breaking Biology Technology:Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 2TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 3TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 4HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 2HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 3
... Dendreon Corporation (Nasdaq: DNDN ) management will host a conference call ... second quarter 2009 financial results. Access to the discussion may be obtained as ... 11:30 AM ET /8:30 AM PT, Date: ... (domestic) or +1-719-325-4873 (international), Webcast: www.dendreon.com (homepage and investor ...
... , , , PITTSBURGH, July 30 ... the three and six months ended June 30, 2009. , , ... Adjusted diluted EPS, which excludes the impact of certain purchase accounting items ... $0.65 for the three and six months ended June 30, 2009, compared to $0.20 ...
... a weakened strain of the malaria parasite that will be ... developed in collaboration with researchers from the US, Japan and ... Malaria kills more than one million people each year and ... of at least 35 million years of healthy, productive human ...
Cached Biology Technology:Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET 2Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 2Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 3Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 4Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 5Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 6Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 7Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 8Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 9Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 10Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 11Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 12Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 13Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 14Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 15Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 16Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 17Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 18First genetically engineered malaria vaccine to enter human trials 2
(Date:6/17/2015)... SAN JOSE, Calif. , June 17, 2015 ... leader in human interface solutions, today announced that ... has adopted the Synaptics ® ClearPad ® ... family of display driver integrated circuits (DDICs) for ... Note Pro. By leveraging ClearPad for full in-cell ...
(Date:6/16/2015)... 16, 2015 Fingerprint Cards (FPC) raises ... it will amount to at least 340 MSEK to that ... rapid increase in market growth and orders received the revenue ... that revenue for 2015 will exceed 1,500 MSEK to an ... 2,200 MSEK. Due to receipt of orders of ...
(Date:6/11/2015)... June 11, 2015 Daon, a global ... that its IdentityX Mobile Authentication Platform v4.0 has ... Alliance is an industry consortium launched in 2013 ... simpler, stronger authentication.  In order to receive certification, ... rigorous series of tests that measure compliance and ...
Breaking Biology News(10 mins):Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... protective delivery vehicle that shuttles friendly bacteria safely through ... boost for the probiotics industry. The new technology ... drugs and even increase calcium absorption, according to research ... at the University of York this week. The ...
... coli strain that hit Germany in May 2011 ... of collaboration across the scientific community should give insight ... the Society for General Microbiology,s Autumn Conference 2011. ... BGI, China. Their sequence was provided in draft form ...
... this math more evident than in vertebrates, which are programmed ... do not. Snakes, of course, have no digits, and birds ... handle on how these developmental changes are orchestrated in the ... Which digits are they: a thumb with index and middle ...
Cached Biology News:New polymer research could boost probiotics industry 2Crowd-sourcing the E. coli O104:H4 outbreak 2
... 8 micro-bore tubes to 1 outflow ... tips, Rapid (several millisecond) solution change ... prevention , Solid construction 360, 250 ... For mounting on any micromanipulator Available ...
... (BTI-TN-5B1-4) derived from Trichoplusia ni egg ... be capable of expressing significantly higher ... to other insect cells. High Five ... time as adherent cultures- Quick adaptation into ...
... Racks are ideal for storage and transport ... polypropylene racks withstand extreme temperatures, making them ... may also be autoclaved for use in ... side accommodates 0.5ml microcentrifuge tubes, the other ...
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
Biology Products: